This clinical trial is to evaluate the experimental (investigational) study drug Elafibranor in men or women who have been diagnosed with Primary Biliary Cholangitis (PBC). Primary Biliary Cholangitis (PBC) is a chronic liver disease resulting from progressive destruction of the liver bile ducts. Elafibranor is considered to be experimental meaning it is not approved by the U.S. Food and Drug Administration (FDA).
   
This study is being conducted to learn more about the effects and safety of the study drug Elafibranor and compare the study drug with placebo (inactive ingredient). Eligible participants will be randomized (like a flip of a coin) to receive Elafibranor 80mg or placebo.
   
This study requires participants to arrive at the clinic over a period of approximately 6 years (72 months). Study participants will be compensated for their time.